C3 treats first European patient with CellSpray

By Helen Schuller
Friday, 28 October, 2005

Tissue engineering specialist Clinical Cell Culture (ASX:CCE, C3) has treated a first European patient with its burns therapy CellSpray at Halle, in Germany.

CellSpray is intended for use in patients with between 30 per cent and 90 per cent of injuries to the body surface. It was launched in Europe in September, at the European Burns Association meeting in Portugal. Surgeons and medical practitioners in 20 hospitals in German speaking countries have been trained in using the CellSpray technology.

In July, the first patient was treated with C3's CellSpray XP, which is intended for use in patients with injuries of 10 to 30 per cent of the body.

CellSpray is available for sale in Austria, Denmark, Germany, The Netherlands and the UK, while CellSpray XP is also available for sale in Switzerland and Italy.

Related News

Free meningococcal B vaccines coming to the NT

The Northern Territory Government has confirmed the rollout of a free meningococcal B vaccine...

Mouth bacteria linked to increased head and neck cancer risk

More than a dozen bacterial species that live in people's mouths have been linked to a...

Life expectancy gains are slowing, study finds

Life expectancy at birth in the world's longest-living populations has increased by an...


  • All content Copyright © 2024 Westwick-Farrow Pty Ltd